Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 175

1.

An analysis of implantable cardiac device reliability. The case for improved postmarketing risk assessment and surveillance.

Laskey W, Awad K, Lum J, Skodacek K, Zimmerman B, Selzman K, Zuckerman B.

Am J Ther. 2012 Jul;19(4):248-54. doi: 10.1097/MJT.0b013e3182512ca5.

PMID:
22668602
2.

Pacemaker and ICD generator malfunctions: analysis of Food and Drug Administration annual reports.

Maisel WH, Moynahan M, Zuckerman BD, Gross TP, Tovar OH, Tillman DB, Schultz DB.

JAMA. 2006 Apr 26;295(16):1901-6.

PMID:
16639048
3.

Longevity of implantable cardioverter-defibrillators for cardiac resynchronization therapy in current clinical practice: an analysis according to influencing factors, device generation, and manufacturer.

Landolina M, Curnis A, Morani G, Vado A, Ammendola E, D'onofrio A, Stabile G, Crosato M, Petracci B, Ceriotti C, Bontempi L, Morosato M, Ballari GP, Gasparini M.

Europace. 2015 Aug;17(8):1251-8. doi: 10.1093/europace/euv109. Epub 2015 May 14.

4.

Impact of manufacturer advisories and FDA recalls of implantable cardioverter defibrillator generators in pediatric and congenital heart disease patients.

Mahajan T, Dubin AM, Atkins DL, Bradley DJ, Shannon KM, Erickson CC, Franklin WH, Cecchin F, Berul CI; Members of the Pediatric and Congenital Electrophysiology Society..

J Cardiovasc Electrophysiol. 2008 Dec;19(12):1270-4. doi: 10.1111/j.1540-8167.2008.01259.x. Epub 2008 Aug 8.

PMID:
18691353
5.

Battery longevity in cardiac resynchronization therapy implantable cardioverter defibrillators.

Alam MB, Munir MB, Rattan R, Flanigan S, Adelstein E, Jain S, Saba S.

Europace. 2014 Feb;16(2):246-51. doi: 10.1093/europace/eut301. Epub 2013 Oct 6.

PMID:
24099864
6.

Effect of bioimpedance body composition analysis on function of implanted cardiac devices.

Buch E, Bradfield J, Larson T, Horwich T.

Pacing Clin Electrophysiol. 2012 Jun;35(6):681-4. doi: 10.1111/j.1540-8159.2012.03377.x. Epub 2012 Mar 27.

PMID:
22452409
7.

Predictors of appropriate defibrillator therapy among patients with an implantable defibrillator that delivers cardiac resynchronization therapy.

Desai AD, Burke MC, Hong TE, Kim S, Salem Y, Yong PG, Knight BP.

J Cardiovasc Electrophysiol. 2006 May;17(5):486-90.

PMID:
16684019
8.

Implantation-related complications of implantable cardioverter-defibrillators and cardiac resynchronization therapy devices: a systematic review of randomized clinical trials.

van Rees JB, de Bie MK, Thijssen J, Borleffs CJ, Schalij MJ, van Erven L.

J Am Coll Cardiol. 2011 Aug 30;58(10):995-1000. doi: 10.1016/j.jacc.2011.06.007. Review.

9.

Multi-Center, Community-Based Cardiac Implantable Electronic Devices Registry: Population, Device Utilization, and Outcomes.

Gupta N, Kiley ML, Anthony F, Young C, Brar S, Kwaku K.

J Am Heart Assoc. 2016 Mar 9;5(3):e002798. doi: 10.1161/JAHA.115.002798.

10.

Recalls and safety alerts involving pacemakers and implantable cardioverter-defibrillator generators.

Maisel WH, Sweeney MO, Stevenson WG, Ellison KE, Epstein LM.

JAMA. 2001 Aug 15;286(7):793-9.

PMID:
11497532
11.

Real-world data on the lifespan of implantable cardioverter-defibrillators depending on manufacturers and the amount of ventricular pacing.

Horlbeck FW, Mellert F, Kreuz J, Nickenig G, Schwab JO.

J Cardiovasc Electrophysiol. 2012 Dec;23(12):1336-42. doi: 10.1111/j.1540-8167.2012.02408.x. Epub 2012 Aug 21.

PMID:
22909190
12.

A protocol for patients with cardiovascular implantable devices undergoing magnetic resonance imaging (MRI): should defibrillation threshold testing be performed post-(MRI).

Burke PT, Ghanbari H, Alexander PB, Shaw MK, Daccarett M, Machado C.

J Interv Card Electrophysiol. 2010 Jun;28(1):59-66. doi: 10.1007/s10840-009-9463-y. Epub 2010 Jan 29.

PMID:
20111895
13.

Changing trends in pacemaker and implantable cardioverter defibrillator generator advisories.

Maisel WH, Stevenson WG, Epstein LM.

Pacing Clin Electrophysiol. 2002 Dec;25(12):1670-8.

PMID:
12520666
15.

Is implantable defibrillator indicated in all patients on cardiac resynchronization therapy?

Pieragnoli P, Ricciardi G, Colella A, Musilli N, Porciani MC, Giaccardi M, Padeletti L, Michelucci A.

Minerva Cardioangiol. 2006 Dec;54(6):735-41. Review.

PMID:
17167385
16.

Sprint Fidelis lead fractures in patients with cardiac resynchronization therapy devices: insight from the Resynchronization/Defibrillation for Ambulatory Heart Failure (RAFT) study.

Parkash R, Thibault B, Sterns L, Sapp J, Krahn A, Talajic M, Luce M, Yetisir E, Theoret-Patrick P, Wells G, Tang A.

Circulation. 2012 Dec 18;126(25):2928-34. doi: 10.1161/CIRCULATIONAHA.112.132100. Epub 2012 Nov 16.

17.

Left ventricular mechanical assist devices and cardiac device interactions: an observational case series.

Foo D, Walker BD, Kuchar DL, Thorburn CW, Tay A, Hayward CS, Macdonald P, Keogh A, Kotlyar E, Spratt P, Jansz P.

Pacing Clin Electrophysiol. 2009 Jul;32(7):879-87. doi: 10.1111/j.1540-8159.2009.02403.x.

PMID:
19572863
18.
19.

Medical device tracking: results of a case study of the implantable cardioverter defibrillator.

Kaczmarek RG, Beaulieu MD, Kessler LG.

Am J Cardiol. 2000 Mar 1;85(5):588-92.

PMID:
11078272
20.

Implantable cardioverter-defibrillator patients who are upgraded and respond to cardiac resynchronization therapy have less ventricular arrhythmias compared with nonresponders.

Thijssen J, Borleffs CJ, Delgado V, van Rees JB, Mooyaart EA, van Bommel RJ, van Erven L, Boersma E, Bax JJ, Schalij MJ.

J Am Coll Cardiol. 2011 Nov 22;58(22):2282-9. doi: 10.1016/j.jacc.2011.08.038.

Supplemental Content

Support Center